GlassScriptPhysician profile
Althea L Alexis
NPI 1457476939
$4,102.32
in general payments reported to CMS, 2019-2025
36 companies · $499 in 2025
The $499 reported for 2025 was more than what 80% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $621 · 2020: $371 · 2021: $862 · 2022: $376 · 2023: $983 · 2024: $391 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,410 · Education: $463.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,409.78 |
| Education | $462.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $892.20 | 2019-2023 | Lo Loestrin Fe |
| Astellas Pharma US INC | $762.78 | 2019-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $310.09 | 2019-2025 | Slynd, Nuvessa, Tyblume |
| Mayne Pharma Commercial LLC | $238.60 | 2021-2025 | |
| Millicent US INC | $198.46 | 2022-2024 | Intrarosa |
| Evofem Biosciences, INC. | $174.87 | 2020-2022 | |
| Therapeuticsmd, INC. | $146.91 | 2019-2022 | |
| Pfizer INC. | $122.23 | 2019-2024 | |
| Amag Pharmaceuticals, INC. | $111.75 | 2019 | |
| Aspira Women'S Health INC | $107.56 | 2019-2021 | |
| Organon LLC | $96.61 | 2022-2024 | Nexplanon, Nuvaring |
| Lupin INC. | $87.79 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $82.50 | 2019-2025 | |
| Scynexis, INC. | $71.39 | 2021-2022 | |
| Agile Therapeutics, INC. | $68.97 | 2021 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ascend Therapeutics US, LLC | $61.55 | 2020-2023 | |
| Hologic Sales and Service, LLC | $56.98 | 2020-2023 | Acessa Provu System |
| Allergan, INC. | $53.75 | 2019-2020 | |
| Minerva Surgical, INC | $49.96 | 2023 | |
| Avion Pharmaceuticals | $47.35 | 2019-2021 | |
| Exact Sciences Corporation | $45.56 | 2025 | Cologuard Collection Kit |
| Mylan Pharmaceuticals INC. | $43.05 | 2020-2021 | |
| Ethicon US, LLC | $34.60 | 2024-2025 | Vistaseal, Enseal, Stratafix |
| Shield Therapeutics INC | $33.31 | 2023 | Accrufer |
| Molnlycke Health Care US, LLC | $31.03 | 2023 | Avance, Mepilex Border Post-Op Ag |
| Daiichi Sankyo INC. | $28.34 | 2023 | Injectafer |
| Pacira Pharmaceuticals Incorporated | $20.26 | 2025 | Exparel |
| Virtus Pharmaceuticals LLC | $19.32 | 2021 | |
| Medtronic, INC. | $19.06 | 2023 | Ligasure |
| Sumitomo Pharma America, INC. | $17.90 | 2023 | Myfembree |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.71 | 2024 | Xifaxan |
| Amgen INC. | $14.83 | 2019 | |
| Coopersurgical, INC. | $13.17 | 2022 | |
| Mission Pharmacal Company | $12.78 | 2021 | |
| Merck Sharp & Dohme LLC | $11.10 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Althea Alexis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.